Patents by Inventor Hendricus Marie Janssen
Hendricus Marie Janssen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240091371Abstract: The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.Type: ApplicationFiled: October 30, 2023Publication date: March 21, 2024Applicant: Tagworks Pharmaceuticals B.V.Inventors: Marc Stefan ROBILLARD, Hendricus Marie JANSSEN, Wolter TEN HOEVE, Ronny Mathieu VERSTEEGEN, Raffaella ROSSIN
-
Patent number: 11857636Abstract: The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.Type: GrantFiled: February 5, 2021Date of Patent: January 2, 2024Assignee: TAGWORKS PHARMACEUTICALS B.V.Inventors: Marc Stefan Robillard, Hendricus Marie Janssen, Wolter Ten Hoeve, Ronny Mathieu Versteegen, Raffaella Rossin
-
Publication number: 20230144534Abstract: Disclosed is an advancement in provoked chemical cleavage. Thereby the invention provides the use of a diene as a chemically cleavable group attached to a Construct, and the use of a dienophile to provoke the release of the Construct by allowing the diene to react with a dienophile capable of undergoing an inverse electron demand Diels Alder reaction with the diene. The invention includes a kit for releasing a Construct CA bound to a Trigger TR, the kit having a tetrazine and a dienophile, wherein the Trigger is the tetrazine. The invention also includes the use of the formation of a pyridazine by reacting a tetrazine having a Construct CA bound thereto and a dienophile, as a chemical tool for the release, in a chemical, biological or physiological environment, of the Construct.Type: ApplicationFiled: September 20, 2022Publication date: May 11, 2023Applicants: TAGWORKS PHARMACEUTICALS B.V., SYNCOM B.V.Inventors: Marc Stefan ROBILLARD, Wolter TEN HOEVE, Freek Johannes Maria HOEBEN, Ronny Mathieu VERSTEEGEN, Hendricus Marie JANSSEN, Arthur Henry Antoon Marie VAN ONZEN, Raffaella ROSSIN
-
Patent number: 11617799Abstract: Disclosed is an advancement in provoked chemical cleavage. Thereby the invention provides the use of a diene as a chemically cleavable group attached to a Construct, and the use of a dienophile to provoke the release of the Construct by allowing the diene to react with a dienophile capable of undergoing an inverse electron demand Diels Alder reaction with the diene. The invention includes a kit for releasing a Construct CA bound to a Trigger TR, the kit having a tetrazine and a dienophile, wherein the Trigger is the tetrazine. The invention also includes the use of the formation of a pyridazine by reacting a tetrazine having a Construct CA bound thereto and a dienophile, as a chemical tool for the release, in a chemical, biological or physiological environment, of the Construct.Type: GrantFiled: June 27, 2017Date of Patent: April 4, 2023Assignees: TAGWORKS PHARMACEUTICALS B.V., SYNCOM B.V.Inventors: Marc Stefan Robillard, Wolter Ten Hoeve, Freek Johannes Maria Hoeben, Ronny Mathieu Versteegen, Hendricus Marie Janssen, Arthur Henry Antoon Marie Van Onzen, Raffaella Rossin
-
Publication number: 20210162060Abstract: The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.Type: ApplicationFiled: February 5, 2021Publication date: June 3, 2021Applicant: TAGWORKS PHARMACEUTICALS B.V.Inventors: Marc Stefan ROBILLARD, Hendricus Marie JANSSEN, Wolter TEN HOEVE, Ronny Mathieu VERSTEEGEN, Raffaella ROSSIN
-
Patent number: 10967069Abstract: The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.Type: GrantFiled: July 15, 2019Date of Patent: April 6, 2021Assignee: TAGWORKS PHARMACEUTICALS B.V.Inventors: Marc Stefan Robillard, Hendricus Marie Janssen, Wolter Ten Hoeve, Ronny Mathieu Versteegen, Raffaella Rossin
-
Publication number: 20190336612Abstract: The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.Type: ApplicationFiled: July 15, 2019Publication date: November 7, 2019Applicant: TAGWORKS PHARMACEUTICALS B.V.Inventors: Marc Stefan ROBILLARD, Hendricus Marie JANSSEN, Wolter TEN HOEVE, Ronny Mathieu VERSTEEGEN, Raffaella ROSSIN
-
Publication number: 20190247513Abstract: Disclosed is an advancement in provoked chemical cleavage. Thereby the invention provides the use of a diene as a chemically cleavable group attached to a Construct, and the use of a dienophile to provoke the release of the Construct by allowing the diene to react with a dienophile capable of undergoing an inverse electron demand Diels Alder reaction with the diene. The invention includes a kit for releasing a Construct CA bound to a Trigger TR, the kit comprising a tetrazine and a dienophile, wherein the Trigger is the tetrazine. The invention also includes the use of the formation of a pyridazine by reacting a tetrazine comprising a Construct CA bound thereto and a dienophile, as a chemical tool for the release, in a chemical, biological or physiological environment, of said Construct.Type: ApplicationFiled: June 27, 2017Publication date: August 15, 2019Applicant: Tagworks Pharmaceuticals B.V.Inventors: Marc Stefan ROBILLARD, Wolter TEN HOEVE, Freek Johannes Maria HOEBEN, Ronny Mathieu VERSTEEGEN, Hendricus Marie JANSSEN, Arthur Henry Antoon Marie VAN ONZEN, Raffaella ROSSIN
-
Patent number: 10376594Abstract: The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.Type: GrantFiled: December 30, 2015Date of Patent: August 13, 2019Assignee: TAGWORKS PHARMACEUTICALS B.V.Inventors: Marc Stefan Robillard, Hendricus Marie Janssen, Wolter Ten Hoeve, Ronny Mathieu Versteegen, Raffaella Rossin
-
Patent number: 10004810Abstract: The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.Type: GrantFiled: November 23, 2016Date of Patent: June 26, 2018Assignee: TAGWORKS PHARMACEUTICALS B.V.Inventors: Marc Stefan Robillard, Hendricus Marie Janssen, Wolter Ten Hoeve, Ronny Mathieu Versteegen
-
Patent number: 9931408Abstract: The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.Type: GrantFiled: May 16, 2012Date of Patent: April 3, 2018Assignee: KONINKLIJKE PHILIPS N.V.Inventors: Marc Stefan Robillard, Hendricus Marie Janssen, Wolter Ten Hoeve, Ronny Mathieu Versteegen, Raffaella Rossin
-
Publication number: 20170143840Abstract: The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.Type: ApplicationFiled: November 23, 2016Publication date: May 25, 2017Inventors: Marc Stefan Robillard, Hendricus Marie Janssen, Wolter Ten Hoeve, Ronny Mathieu Versteegen
-
Patent number: 9421274Abstract: The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.Type: GrantFiled: May 16, 2012Date of Patent: August 23, 2016Assignee: Koninklijke Philips N.V.Inventors: Marc Stefan Robillard, Hendricus Marie Janssen, Wolter Ten Hoeve, Ronny Mathieu Versteegen
-
Publication number: 20160106859Abstract: The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.Type: ApplicationFiled: December 30, 2015Publication date: April 21, 2016Inventors: MARC STEFAN ROBILLARD, HENDRICUS MARIE JANSSEN, WOLTER TEN HOEVE, RONNY MATHIEU VERSTEEGEN, RAFFAELLA ROSSIN
-
Publication number: 20140199331Abstract: The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.Type: ApplicationFiled: May 16, 2012Publication date: July 17, 2014Applicant: KONINKLIJKE PHILIPS N.V.Inventors: Marc Stefan Robillard, Hendricus Marie Janssen, Wolter Ten Hoeve, Ronny Mathieu Versteegen
-
Publication number: 20140093522Abstract: The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.Type: ApplicationFiled: May 16, 2012Publication date: April 3, 2014Applicant: KONINKLIJKE PHILIPS N.V.Inventors: Marc Stefan Robillard, Hendricus Marie Janssen, Wolter Ten Hoeve, Ronny Mathieu Versteegen, Raffaella Rossin
-
Patent number: 8247524Abstract: The present invention relates to a supramolecular polymer comprising quadruple hydrogen bonding units within the polymer backbone, wherein at least a monomer comprising a 4H-unit is incorporated in the polymer backbone via at least two reactive groups up to four reactive groups, provided that the 4H-units are not covalently incorporated in the polymer backbone through one or more silicon-carbon bonds. The invention also relates to processes for preparing such supramolecular polymers and their use in personal care applications, surface coatings, imaging technologies, biomedical applications, (themo)reversible coatings, adhesive and sealing compositions and as thickening agents, gelling agents and binders.Type: GrantFiled: October 19, 2010Date of Patent: August 21, 2012Assignee: Suprapolix B.V.Inventors: Hendricus Marie Janssen, Gaby Maria Leonarda Van Gemert, Egbert Willem Meijer, Anton Willem Bosman
-
Publication number: 20110034641Abstract: The present invention relates to a supramolecular polymer comprising quadruple hydrogen bonding units within the polymer backbone, wherein at least a monomer comprising a 4H-unit is incorporated in the polymer backbone via at least two reactive groups up to four reactive groups, provided that the 4H-units are not covalently incorporated in the polymer backbone through one or more silicon-carbon bonds. The invention also relates to processes for preparing such supramolecular polymers and their use in personal care applications, surface coatings, imaging technologies, biomedical applications, (themo)reversible coatings, adhesive and sealing compositions and as thickening agents, gelling agents and binders.Type: ApplicationFiled: October 19, 2010Publication date: February 10, 2011Inventors: HENDRICUS MARIE JANSSEN, GABY MARIA LEONARDA VAN GEMERT, EGBERT WILLEM MEIJER, ANTON WILLEM BOSMAN
-
Patent number: 7838621Abstract: The present invention relates to a supramolecular polymer comprising quadruple hydrogen bonding units within the polymer backbone, wherein at least a monomer comprising a 4H-unit is incorporated in the polymer backbone via at least two reactive groups up to four reactive groups, provided that the 4H-units are not covalently incorporated in the polymer backbone through one or more silicon-carbon bonds. The invention also relates to processes for preparing such supramolecular polymers and their use in personal care applications, surface coatings, imaging technologies, biomedical applications, (thermo)reversible coatings, adhesive and sealing compositions and as thickening agents, gelling agents and binders.Type: GrantFiled: November 4, 2003Date of Patent: November 23, 2010Assignee: Suprapolix B.V.Inventors: Hendricus Marie Janssen, Gaby Maria Leonarda Van Gemert, Egbert Willem Meijer, Anton Willem Bosman
-
Patent number: 7622131Abstract: The invention relates to the synthesis of siloxane polymers containing self-complementary quadruple hydrogen bonding groups (4H-units). The resulting polymers show unique new characteristics that result from the reversible, physical interactions between the polysiloxane chains that are based on the (supramolecular) interactions between the 4H-units. The polysiloxanes in this invention show unprecedented bulk material properties and are used as gelling agents for silicone fluids. The resulting gels are clear and display good material properties, while having unparalleled high silicone fluid contents.Type: GrantFiled: June 9, 2005Date of Patent: November 24, 2009Assignee: Suprapolix B.V.Inventors: Anton Willem Bosman, Hendricus Marie Janssen, Gaby Maria Leonarda Van Gemert, Ronny Mathieu Versteegen, Egbert Willem Meijer, Rintje Pieter Sijbesma